Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.72 +1.16%
Revenue Growth %: +30.4%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +30.4%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance
- Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
